呼吸系统与心血管代谢合并症与I至III期非小细胞肺癌生存的关联:国际肺癌联盟汇总分析
该研究基于国际肺癌联盟11项研究的汇总数据,纳入16354例有呼吸或心血管代谢健康数据的NSCLC患者分析总生存,其中11614例用于肺癌特异性生存分析。结果显示,呼吸系统合并症与较差的肺癌特异性生存相关且手术切除率更低,心血管代谢合并症则与竞争性(非NSCLC)死亡风险升高相关,两类合并症均与更差的总生存相关。
要点
- I至IIIA期NSCLC伴呼吸系统合并症者肺癌特异性生存更差,且接受手术切除的可能性更低。
- I至IIIA期NSCLC伴心血管代谢合并症者竞争性(非NSCLC)死亡风险更高。
- 呼吸系统或心血管代谢合并症的存在均与I至III期NSCLC更差的总生存相关。
核心结论
- 呼吸系统或心血管代谢合并症任一存在均与I至III期NSCLC更差的总生存相关。
- 伴呼吸系统合并症者接受手术的可能性更低且肺癌特异性生存更差,伴心血管代谢合并症者竞争性死亡风险更高。
- 随着I至III期NSCLC治疗选择增多,在试验解读与临床管理中考虑心血管代谢和呼吸系统合并症变得至关重要。
研究设计与样本
- 基于国际肺癌联盟11项研究中有呼吸和心血管代谢合并症数据的NSCLC患者汇总数据。
- 总生存分析纳入16354例,肺癌特异性生存分析纳入其中11614例子集。
- 采用Cox模型估计总生存的校正风险比(aHR),采用竞争风险Grey和Fine模型及累积发生率函数评估肺癌特异性生存,采用逻辑回归(校正OR [aOR])评估与手术切除相关的因素。
主要发现
- I至IIIA期NSCLC伴心血管代谢合并症者竞争性(非NSCLC)死亡风险更高:IA期aHR=1.34(95%CI:1.12-1.69)。
- 呼吸系统合并症的存在与接受手术切除呈负相关:IA期aOR=0.54(95%CI:0.35-0.83),IB-IIIA期aOR=0.57(95%CI:0.46-0.70)。
临床怎么用
- 原文结论指出,随着I至III期NSCLC治疗选择增多,在试验解读与临床管理中考虑心血管代谢和呼吸系统合并症变得至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer-specific survival (LCSS), by stage, in a large, multicontinent NSCLC pooled data set. METHODS: On the basis of patients pooled from 11 International Lung Cancer Consortium studies with available respiratory and cardiometabolic comorbidity data, adjusted hazard ratios (aHRs) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted OR [aOR]) was applied to assess factors associated with surgical resection. RESULTS: OS analyses used patients with NSCLC with respiratory health or cardiometabolic health data (N = 16,354); a subset (n = 11,614) contributed to LCSS analyses. In stages I to IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (stage IA aHR = 1.51, confidence interval [CI]: 1.17-1.95; stages IB-IIIA aHR = 1.20, CI: 1.06-1.036). In contrast, patients with stages I to IIIA NSCLC with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (stage IA aHR = 1.34, CI: 1.12-1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (stage IA aOR = 0.54, CI: 0.35-0.83; stages IB-IIIA aOR = 0.57, CI: 0.46-0.70). CONCLUSIONS: The presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in stages I to III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, whereas patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatment options for stages I to III NSCLC are introduced into the practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.
引用
- García-Pardo M, Chang A, Schmid S, et al. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium. J Thorac Oncol. 2022. PMID: 36396063. doi:10.1016/j.jtho.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。